Overview

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

Status:
Completed

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).

Phase:

Phase 3

Details

Lead Sponsor:

German Breast Group

Collaborator:

Pfizer

Treatments:

Aromatase Inhibitors
Exemestane
Goserelin
Prolactin Release-Inhibiting Factors
Tamoxifen